KR100854685B1 - 홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 - Google Patents
홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 Download PDFInfo
- Publication number
- KR100854685B1 KR100854685B1 KR1020080004867A KR20080004867A KR100854685B1 KR 100854685 B1 KR100854685 B1 KR 100854685B1 KR 1020080004867 A KR1020080004867 A KR 1020080004867A KR 20080004867 A KR20080004867 A KR 20080004867A KR 100854685 B1 KR100854685 B1 KR 100854685B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- iii
- concentrate
- ginseng
- red
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 235000008434 ginseng Nutrition 0.000 title claims description 29
- 241000208340 Araliaceae Species 0.000 title claims description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims description 28
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 125
- 239000012141 concentrate Substances 0.000 claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 21
- 238000010438 heat treatment Methods 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012535 impurity Substances 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 8
- 229940107131 ginseng root Drugs 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims description 17
- 235000019698 starch Nutrition 0.000 claims description 17
- 239000008107 starch Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 229930182490 saponin Natural products 0.000 description 16
- 150000007949 saponins Chemical class 0.000 description 16
- 235000017709 saponins Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 15
- 229930182494 ginsenoside Natural products 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 229940089161 ginsenoside Drugs 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003660 reticulum Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001197 polyacetylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- -1 starch Chemical class 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101800000112 Acidic peptide Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- BVMLGLOHSDNEJG-UHFFFAOYSA-N neglschisandrin E Natural products C1C(C)C(C)CC2=CC(O)=C(OC)C(OC)=C2C2=C1C=C1OCOC1=C2OC BVMLGLOHSDNEJG-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
시간(분) | 물(%) | Acetonitrile(%) |
0~10 | 80 | 20 |
10~40 | 80→68 | 20→32 |
40~48 | 68→58 | 32→42 |
48~50 | 58→0 | 42→100 |
50~60 | 0 | 100 |
60~62 | 0→80 | 100→20 |
62~70 | 80 | 20 |
구분 | 임파구 증식능(SI) |
대조군 | PBS : 1.0 |
양성대조군 | Con A : 40.9(2.5 ㎍/㎖) |
실시예 1 | 22.4(500 ㎍/㎖) |
구분 | LAK 세포생성능(lytic units) |
대조군 | PBS : 1.0 |
양성대조군 | IL-2 : 54.6(30 units) |
실시예 1 | 9.7(100 ㎍/㎖) |
Claims (13)
- ⅰ) 원료가 되는 홍삼을 선별 및 열처리하는 단계;ⅱ) 상기 선별된 홍삼에 정제수를 혼합하여 고온에서 추출하는 단계;ⅲ) 상기 추출된 홍삼액을 가열 및 살균처리하는 단계;ⅳ) 상기 살균처리된 홍삼 추출액을 냉각시키고 불순물을 분리제거하는 단계;ⅴ) 상기 불순물이 제거된 홍삼 추출액을 55~65℃의 저온 진공농축방법으로 농축하여 #100~140체에서 불순물을 제거하고 숙성하는 홍삼 추출액의 농축 및 숙성 단계; 및ⅵ) 상기 홍삼 추출액의 당분 및 전분함량을 측정하는 단계를 포함하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅰ) 단계의 선별 및 열처리는 세삼/증삼/건조/정형/선별 공정 및 100~120℃의 열처리 공정으로 이루어지는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅱ) 단계의 정제수는 원료 홍삼 질량의 4~8배인 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅱ) 단계의 고온은 증기 간접 가열방식으로 80~95℃인 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅱ) 단계의 추출은 연속식 탱크에서 5~8회 수행하거나 배치식 탱크에서 2~5회 수행하는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅲ) 단계의 가열 및 살균처리는 90~100℃에서 가열 및 순간 냉각/가열 방법으로 살균처리하는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅳ) 단계의 냉각은 0~10℃에서 수행하는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅳ) 단계의 불순물의 제거는 5,000~8,000 rpm의 원심분리기를 이용하여 10~30 ℓ/min의 유속으로 냉각 호화된 전분질 및 이물 찌꺼기를 제거하는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 삭제
- 제 1항에 있어서, 상기 ⅵ) 단계의 당분 및 전분함량 측정은 40~75 브릭스의 당분 함량 및 2~3% 전분 함량인 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 ⅵ) 단계 이후에 홍삼 농축액의 색도, 수분함량 및 미생물 분석을 수행하며, 상기 색도는 0.20~0.50이고, 수분함량은 30~45%이고, 미생물은 100/g 이하인 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항에 있어서, 상기 원료가 되는 홍삼은 홍삼근: 홍미삼 의비가 1: 1~0.2로 함유되는 것을 특징으로 하는 홍삼 농축액의 제조방법.
- 제 1항 내지 제 8항 및 제 10항 내지 제 12항 중 어느 한 항의 방법에 의하여 제조된 홍삼 농축액.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080004867A KR100854685B1 (ko) | 2008-01-16 | 2008-01-16 | 홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080004867A KR100854685B1 (ko) | 2008-01-16 | 2008-01-16 | 홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100854685B1 true KR100854685B1 (ko) | 2008-08-27 |
Family
ID=39878733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080004867A KR100854685B1 (ko) | 2008-01-16 | 2008-01-16 | 홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100854685B1 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100971438B1 (ko) | 2008-05-14 | 2010-07-21 | 동국대학교 경주캠퍼스 산학협력단 | 해양심층수와 열처리 산삼배양근 추출물을 이용한 건강식품및 그 제조방법 |
KR101173353B1 (ko) | 2010-03-16 | 2012-08-10 | (주)풀무원홀딩스 | 진세노사이드 Re 강화 홍삼 농축액 및 이의 제조 방법 |
KR101505103B1 (ko) * | 2013-08-13 | 2015-03-26 | 주식회사 천지양 | 반복 추출을 통한 개선된 홍삼농축액 제조 방법 |
KR101695144B1 (ko) * | 2016-04-21 | 2017-01-11 | 주식회사 로크한삼 | 약재 농축액 제조방법 |
KR20190063080A (ko) * | 2017-11-29 | 2019-06-07 | 고려인삼연구 주식회사 | 고온스트레스에 의해 저하된 면역조절능력을 개선시키는 홍삼추출물 및 이의 제조방법 |
WO2019240497A1 (ko) * | 2018-06-12 | 2019-12-19 | 에스케이바이오랜드 주식회사 | 식물을 원료로 포함하는 겔의 제조방법 |
CN110731445A (zh) * | 2019-11-23 | 2020-01-31 | 吉林省利生源生物制品有限公司 | 一种红参膏的制备方法以及真空浓缩用加热炉 |
KR20230072108A (ko) | 2021-11-17 | 2023-05-24 | 주식회사 엘지생활건강 | 기호성이 증진된 홍삼 농축액의 제조방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030037380A (ko) * | 2001-11-03 | 2003-05-14 | 주식회사 케이티앤지 | 홍삼농축액을 이용한 건강보조식품 및 그의 제조방법 |
KR20040081932A (ko) * | 2003-03-17 | 2004-09-23 | 설혜영 | 홍삼/인삼 신속추출 및 농축액 증대 |
-
2008
- 2008-01-16 KR KR1020080004867A patent/KR100854685B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030037380A (ko) * | 2001-11-03 | 2003-05-14 | 주식회사 케이티앤지 | 홍삼농축액을 이용한 건강보조식품 및 그의 제조방법 |
KR20040081932A (ko) * | 2003-03-17 | 2004-09-23 | 설혜영 | 홍삼/인삼 신속추출 및 농축액 증대 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100971438B1 (ko) | 2008-05-14 | 2010-07-21 | 동국대학교 경주캠퍼스 산학협력단 | 해양심층수와 열처리 산삼배양근 추출물을 이용한 건강식품및 그 제조방법 |
KR101173353B1 (ko) | 2010-03-16 | 2012-08-10 | (주)풀무원홀딩스 | 진세노사이드 Re 강화 홍삼 농축액 및 이의 제조 방법 |
KR101505103B1 (ko) * | 2013-08-13 | 2015-03-26 | 주식회사 천지양 | 반복 추출을 통한 개선된 홍삼농축액 제조 방법 |
KR101695144B1 (ko) * | 2016-04-21 | 2017-01-11 | 주식회사 로크한삼 | 약재 농축액 제조방법 |
KR20190063080A (ko) * | 2017-11-29 | 2019-06-07 | 고려인삼연구 주식회사 | 고온스트레스에 의해 저하된 면역조절능력을 개선시키는 홍삼추출물 및 이의 제조방법 |
KR102129005B1 (ko) * | 2017-11-29 | 2020-07-02 | 고려인삼연구 주식회사 | 고온스트레스에 의해 저하된 면역조절능력을 개선시키는 홍삼추출물 및 이의 제조방법 |
WO2019240497A1 (ko) * | 2018-06-12 | 2019-12-19 | 에스케이바이오랜드 주식회사 | 식물을 원료로 포함하는 겔의 제조방법 |
CN110731445A (zh) * | 2019-11-23 | 2020-01-31 | 吉林省利生源生物制品有限公司 | 一种红参膏的制备方法以及真空浓缩用加热炉 |
KR20230072108A (ko) | 2021-11-17 | 2023-05-24 | 주식회사 엘지생활건강 | 기호성이 증진된 홍삼 농축액의 제조방법 |
JP7479747B2 (ja) | 2021-11-17 | 2024-05-09 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 嗜好性が向上した紅参濃縮液の製造方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100854685B1 (ko) | 홍삼 농축액의 제조방법 및 상기 방법에 의하여 제조된홍삼 농축액 | |
CN100560579C (zh) | 红豆越橘提取物及其制备方法和应用 | |
CN1271083C (zh) | 从竹子中提取的三萜总皂甙元的组成、方法及其用途 | |
KR101144920B1 (ko) | 홍삼 및 식물추출물이 함유된 홍삼정 | |
WO2022116807A1 (zh) | 一种富含灵芝三萜的灵芝萃取油的制备方法 | |
KR100833996B1 (ko) | 미크론 이하 크기의 홍삼 나노분말의 제조방법과 상기방법으로 제조된 홍삼 나노분말 | |
KR101172595B1 (ko) | 꽈리 추출물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물 | |
KR101769184B1 (ko) | 진세노사이드 Rd가 강화된 발효 인삼 또는 홍삼 추출물의 제조방법 | |
KR100557779B1 (ko) | 집중력 및 기억력 저하의 예방 또는 개선을 위한 인삼조성물 | |
KR20120003693A (ko) | 적포도 추출물, 녹차 추출물, 대두 추출물 및 l-카르니틴을 유효성분으로 함유하는 항비만 조성물 | |
KR100854698B1 (ko) | 홍삼 식이섬유 추출방법 및 상기 방법에 의하여 추출된홍삼 식이섬유 | |
KR20180090198A (ko) | 몰로키아 잎 추출물을 유효성분으로 포함하는 면역증강용 조성물 | |
KR20120125152A (ko) | 유산균에 의해 발효된 천마 추출물을 포함하는 항산화용 또는 혈압 조절용 식품 조성물 | |
KR101605057B1 (ko) | 진세노사이드 Rd가 강화된 발효 인삼 또는 홍삼 추출물을 포함하는 아토피 피부염 개선용 조성물 | |
WO2002011744A1 (fr) | Capsule renfermant des antioxydants de type opc (oligomeres procyanidoliques ) a base d'extrait de pepins de raisin et son procede de preparation | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR101061575B1 (ko) | 홍삼 및 식물추출물이 함유된 음료 | |
KR20120059258A (ko) | 생물 활성을 가지는 한방식재료 추출액 및 이의 제조방법 | |
KR101771788B1 (ko) | 신경 질환의 예방 및 개선용 발효황금 천마복합액의 제조방법 | |
CN116019187A (zh) | 一种天然来源的抗糖化组合物及其制备方法和在口服美容产品中的用途 | |
KR100854688B1 (ko) | 홍삼 농축액을 함유한 기능성 음료 | |
KR101413283B1 (ko) | 면역력 증강을 위한 면역증강복합물을 이용한 인삼 조성물 제조방법 및 인삼 조성물 | |
CN113648347A (zh) | 含莲子外泌体的卵巢保养的组合物及其制备方法 | |
Garmashov et al. | Technological parameters of countercurrent extraction: deriving bioactive compounds from plant raw materials | |
KR100854700B1 (ko) | 홍삼 농축액을 함유한 기능성 음료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120730 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130722 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140804 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150723 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160801 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170728 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190718 Year of fee payment: 12 |